Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials

scientific article published on 23 June 2016

Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1093/HUMREP/DEW149
P698PubMed publication ID27343272

P50authorPaul DevroeyQ7150251
Peter HumaidanQ54217726
P2093author name stringL B Schwartz
K Gordon
B C Tarlatzis
J L Frattarelli
B J Stegmann
C C Coddington
H M Fatemi
P Lutjen
S M Nelson
P2860cites workDistinction between early and late ovarian hyperstimulation syndromeQ48891954
Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilizationQ48919257
Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndromeQ58377209
Hydroxyethyl StarchesQ29011237
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a reviewQ30877789
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites ClubQ33966809
Role of vascular endothelial growth factor in ovarian physiology and pathologyQ34023513
Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).Q34183801
Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane reviewQ35011448
New concepts in the understanding of the ovarian hyperstimulation syndromeQ35176568
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) TherapyQ36060453
Symposium: Update on prediction and management of OHSS. A modern classification of OHSS.Q37539018
Preventing ovarian hyperstimulation syndrome: guidance for the clinician.Q37736733
An OHSS-Free Clinic by segmentation of IVF treatmentQ37914493
Safety of modern starches used during surgeryQ38056899
Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statementQ38250026
Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three casesQ38253309
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cyclesQ42166546
The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factorQ42468683
Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcomeQ43408204
Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled studyQ43625247
Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.Q43917543
Elective frozen replacement cycles for all: ready for prime time?Q44478394
Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programmeQ44659290
Maternal death related to IVF in the Netherlands 1984-2008.Q44915965
Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilizationQ45773434
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.Q45927696
Worldwide survey of IVF practices: trigger, retrieval and embryo transfer techniquesQ46802412
GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'.Q48597751
International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009.Q48667199
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproductionQ48794435
Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled studyQ48819444
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectovarian hyperstimulation syndromeQ1760461
P304page(s)1997-2004
P577publication date2016-06-23
P1433published inHuman ReproductionQ5937357
P1476titleOvarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials
P478volume31

Reverse relations

cites work (P2860)
Q38371465A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial
Q36375024Analysis of Chromosome Segregation, Histone Acetylation, and Spindle Morphology in Horse Oocytes
Q49988311Clinical parameters of ovarian hyperstimulation syndrome (OHSS) following different hormonal triggers of oocyte maturation in IVF treatment.
Q60907354Effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilisation in women with high antral follicle count: study protocol for a randomised controlled trial
Q51739856Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention.
Q88991253Genome-wide screening differential long non-coding RNAs expression profiles discloses its roles involved in OHSS development
Q33770533GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis
Q94335455Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing IVF/ICSI
Q47848951Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder
Q33883193Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys
Q48510887Ovarian Follicular Theca Cell Recruitment, Differentiation, and Impact on Fertility: 2017 Update
Q51110367Prevention and management of ovarian hyperstimulation syndrome.
Q41148132Quadrupling efficiency in production of genetically modified pigs through improved oocyte maturation
Q60922316Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients
Q90171167TGF-β1 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome
Q92099877The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation
Q38602011Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health

Search more.